Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
DOUBLE-STRANDED OLIGO RNA STRUCTURE COMPRISING MICRORNA
Document Type and Number:
WIPO Patent Application WO/2018/038558
Kind Code:
A1
Abstract:
The present invention relates to a double-stranded oligo RNA structure comprising double-stranded miRNA, and a composition for preventing or treating cancer, containing the same. More specifically, the present invention relates to an anti-cancer pharmaceutical composition, containing: a double-stranded oligo RNA structure comprising miR-3670, miR-4477a and miR-8078, and characterized by a method for effectively inhibiting cancer cell proliferation or inducing cancer cell apoptosis; and a pharmaceutically acceptable carrier.

Inventors:
LEE TAEWOO (KR)
SHIM SANGHYUNG (KR)
YU UNGSIK (KR)
PARK HAN OH (KR)
Application Number:
PCT/KR2017/009271
Publication Date:
March 01, 2018
Filing Date:
August 24, 2017
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
BIONEER CORP (KR)
International Classes:
C12N15/113; A61K31/7105
Domestic Patent References:
WO2014100252A12014-06-26
Foreign References:
KR20160033125A2016-03-25
KR20090081125A2009-07-28
KR101224828B12013-01-22
KR100883471B12009-02-16
KR101224828B12013-01-22
Other References:
DATABASE Nucleotide [O] 2 July 2015 (2015-07-02), XP055556728, Database accession no. AC269968.1
See also references of EP 3505630A4
IORNS, E.; LORD, C.J.; TURNER, N.; ASHWORTH, A.: "Utilizing RNA interference to enhance cancer drug discovery", NAT REV DRUG DISCOV, vol. 6, 2007, pages 556 - 68, XP002675209, DOI: doi:10.1038/nrd2355
TOMARI, Y.; ZAMORE, P.D.: "Perspective: machines for RNAi", GENES DEV, vol. 19, 2005, pages 517 - 29
CHU, C.Y.; RANA, T.M.: "Potent RNAi by short RNA triggers", RNA, vol. 14, 2008, pages 1714 - 9, XP055474297, DOI: doi:10.1261/rna.1161908
MITTAL, V.: "Improving the efficiency of RNA interference in mammals", NAT REV GENET, vol. 5, 2004, pages 355 - 65, XP002597964, DOI: doi:10.1038/NRG1323
REYNOLDS, A. ET AL.: "Rational siRNA design for RNA interference", NAT BIOTECHNOL, vol. 22, 2004, pages 326 - 30, XP002311429, DOI: doi:10.1038/nbt936
JACKSON, A.L. ET AL.: "Widespread siRNA ''off-target'' transcript silencing mediated by seed region sequence complementarity", RNA, vol. 12, 2006, pages 1179 - 87, XP002569696, DOI: doi:10.1261/rna.25706
JACKSON, A.L. ET AL.: "Position-specific chemical modification of siRNAs reduces ''off-target'' transcript silencing", RNA, vol. 12, 2006, pages 1197 - 205
JACKSON, A.L. ET AL.: "Expression profiling reveals off-target gene regulation by RNAi", NAT BIOTECHNOL, vol. 21, 2003, pages 635 - 7, XP002569694, DOI: doi:10.1038/nbt831
NIELSEN, C.B. ET AL.: "Determinants of targeting by endogenous and exogenous microRNAs and siRNAs", RNA, vol. 13, 2007, pages 1894 - 910
PEEK, A.S.; BEHLKE, M.A.: "Design of active small interfering RNAs", CURR OPIN MOL THER, vol. 9, 2007, pages 110 - 8
AGOSTINI, M.; KNIGHT, R.A.: "miR-34: from bench to bedside", ONCOTARGET, vol. 5, 2014, pages 872 - 81
VAN ROOIJ; E., PURCELL; A.L.; LEVIN; A.A.: "Developing MicroRNA Therapeutics", CIRCULATION RESEARCH, vol. 110, 2012, pages 496 - 507, XP055144403, DOI: doi:10.1161/CIRCRESAHA.111.247916
BURNETT; J.C.; ROSSI, J.J.: "RNA-based therapeutics: current progress and future prospects", CHEM BIOL, vol. 19, 2012, pages 60 - 71, XP055087578, DOI: doi:10.1016/j.chembiol.2011.12.008
DANGWAL, S.; THUM, T.: "microRNA therapeutics in cardiovascular disease models", ANNU REV PHARMACOL TOXICOL, vol. 54, 2014, pages 185 - 203, XP055449738, DOI: doi:10.1146/annurev-pharmtox-011613-135957
CARTHEW, R.W.; SONTHEIMER, E.J.: "Origins and Mechanisms of miRNAs and siRNAs", CELL, vol. 136, 2009, pages 642 - 55, XP055091221, DOI: doi:10.1016/j.cell.2009.01.035
MACFARLANE, L.-A.; MURPHY, P.R.: "MicroRNA: Biogenesis, Function and Role in Cancer", CURRENT GENOMICS, vol. 11, 2010, pages 537 - 561, XP055292126, DOI: doi:10.2174/138920210793175895
BARTEL, D.P.: "MicroRNAs: target recognition and regulatory functions", CELL, vol. 136, 2009, pages 215 - 33, XP055011377, DOI: doi:10.1016/j.cell.2009.01.002
CARTHEW, R.W.; SONTHEIMER, E.J: "Origins and Mechanisms of miRNAs and siRNAs.", CELL, vol. 136, 2009, pages 642 - 55, XP055091221, DOI: doi:10.1016/j.cell.2009.01.035
BRODERSEN, P.; VOINNET, 0.: "Revisiting the principles of microRNA target recognition and mode of action", NAT REV MOL CELL BIOL, vol. 10, 2009, pages 141 - 148
MALONE, C.D.; HANNON, G.J.: "Small RNAs as guardians of the genome", CELL, vol. 136, 2009, pages 656 - 68
NICOLOSO, M.S.; SPIZZO, R.; SHIMIZU, M; ROSSI, S.; CALIN, G.A.: "MicroRNAs-the micro steering wheel of tumour metastases", NAT REV CANCER, vol. 9, 2009, pages 293 - 302
LANDI, D.; GEMIGNANI, F.; LANDI, S.: "Role of variations within microRNA-binding sites in cancer", MUTAGENESIS, vol. 27, 2012, pages 205 - 10
WIGGINS, J.F. ET AL.: "Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34", CANCER RES, vol. 70, 2010, pages 5923 - 30, XP055121667, DOI: doi:10.1158/0008-5472.CAN-10-0655
BADER, A.G. ET AL.: "miR-34 Regulated Genes and Pathways as Targets for Therapeutic Intervention", GOOGLE PATENTS, 2009
HERMEKING, H.: "The miR-34 family in cancer and apoptosis", CELL DEATH DIFFER, vol. 17, 2010, pages 193 - 9, XP055047336, DOI: doi:10.1038/cdd.2009.56
CHANG, T.C. ET AL.: "Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis", MOL CELL, vol. 26, 2007, pages 745 - 52, XP002490192, DOI: doi:10.1016/j.molcel.2007.05.010
NATURE, vol. 432, no. 7014, 2004, pages 173 - 8
J CONTROL RELEASE, vol. 129, no. 2, 2008, pages 107 - 16
OROUJI, E. ET AL.: "MAP Kinase pathway gene copy alterations in NRAS/BRAF wild-type advanced melanoma", INT J CANCER, 2015
ZHENG, C. ET AL.: "MicroRNA-195 functions as a tumor suppressor by inhibiting CBX4 in hepatocellular carcinoma", ONCOL REP, vol. 33, 2015, pages 1115 - 22
JIAO, H.K. ET AL.: "Prognostic significance of Cbx4 expression and its beneficial effect for transarterial chemoembolization in hepatocellular carcinoma", CELL DEATH DIS, vol. 6, 2015, pages e1689
OHASHI, K. ET AL.: "Characteristics of lung cancers harboring NRAS mutations", CLIN CANCER RES, vol. 19, 2013, pages 2584 - 91
MASHIDORI, T.; SHIRATAKI, H.; KAMAI, T.; NAKAMURA, F.; YOSHIDA, K.: "Increased alpha-taxilin protein expression is associated with the metastatic and invasive potential of renal cell cancer", BIOMED RES, vol. 32, 2011, pages 103 - 10
TENNAKOON, S.; AGGARWAL, A.; KALLAY, E.: "The calcium-sensing receptor and the hallmarks of cancer", BIOCHIM BIOPHYS ACTA, 2015
OHTOMO, N. ET AL.: "Expression of alpha-taxilin in hepatocellular carcinoma correlates with growth activity and malignant potential of the tumor", INT J ONCOL, vol. 37, 2010, pages 1417 - 23
LI, Q. ET AL.: "SNIP1: a new activator of HSE signaling pathway", MOL CELL BIOCHEM, vol. 362, 2012, pages 1 - 6, XP035010604, DOI: doi:10.1007/s11010-011-1120-y
FUJII, M. ET AL.: "SNIP1 is a candidate modifier of the transcriptional activity of c-Myc on E box-dependent target genes", MOL CELL, vol. 24, 2006, pages 771 - 83, XP085378840, DOI: doi:10.1016/j.molcel.2006.11.006
ROCHE, K.C.; ROCHA, S.; BRACKEN, C.P.; PERKINS, N.D.: "Regulation of ATR-dependent pathways by the FHA domain containing protein SNIP1", ONCOGENE, vol. 26, 2007, pages 4523 - 30
JEON, H.S. ET AL.: "High expression of SNIP1 correlates with poor prognosis in non-small cell lung cancer and SNIP1 interferes with the recruitment of HDAC1 to RB in vitro", LUNG CANCER, vol. 82, 2013, pages 24 - 30
LIANG, X. ET AL.: "Hypoxia-inducible factor-1 alpha, in association with TWIST2 and SNIP1, is a critical prognostic factor in patients with tongue squamous cell carcinoma", ORAL ONCOL, vol. 47, 2011, pages 92 - 7, XP028136409, DOI: doi:10.1016/j.oraloncology.2010.11.014
PECINA-SLAUS, N. ET AL.: "Wnt signaling transcription factors TCF-1 and LEF-1 are upregulated in malignant astrocytic brain tumors", HISTOL HISTOPATHOL, vol. 29, 2014, pages 1557 - 64
UENO, K. ET AL.: "Tumor suppressor microRNA-493 decreases cell motility and migration ability in human bladder cancer cells by downregulating RhoC and FZD4", MOL CANCER THER, vol. 11, 2012, pages 244 - 53
LIN, Z.Y. ET AL.: "MicroRNA-224 inhibits progression of human prostate cancer by downregulating TRIB1", INT J CANCER, vol. 135, 2014, pages 541 - 50
SOUBEYRAND, S.; NAING, T.; MARTINUK, A.; MCPHERSON, R.: "ERK1/2 regulates hepatocyte Tribl in response to mitochondrial dysfunction", BIOCHIM BIOPHYS ACTA, vol. 1833, 2013, pages 3405 - 14, XP028774021, DOI: doi:10.1016/j.bbamcr.2013.10.001
ZHANG, Q. ET AL.: "Role of microRNA-30c targeting ADAM19 in colorectal cancer", PLOS ONE, vol. 10, 2015, pages e0120698
SHAN, N.; SHEN, L.; WANG, J.; HE, D.; DUAN, C.: "MiR-153 inhibits migration and invasion of human non-small-cell lung cancer by targeting ADAM19", BIOCHEM BIOPHYS RES COMMUN, vol. 456, 2015, pages 385 - 91
MARTENS-DE KEMP, S.R. ET AL.: "Functional genetic screens identify genes essential for tumor cell survival in head and neck and lung cancer", CLIN CANCER RES, vol. 19, 2013, pages 1994 - 2003
RAE, J.M. ET AL.: "GREB1 is a novel androgen-regulated gene required for prostate cancer growth", PROSTATE, vol. 66, 2006, pages 886 - 94
ZHANG, L. ET AL.: "Development of transcriptomic biomarker signature in human saliva to detect lung cancer", CELL MOL LIFE SCI, vol. 69, 2012, pages 3341 - 50, XP035109507, DOI: doi:10.1007/s00018-012-1027-0
LAVIOLETTE, L.A.; HODGKINSON, K.M.; MINHAS, N.; PEREZ-IRATXETA, C.; VANDERHYDEN, B.C.: "17beta-estradiol upregulates GREB1 and accelerates ovarian tumor progression in vivo", INT J CANCER, vol. 135, 2014, pages 1072 - 84
LI, Y. ET AL.: "The HECTD3 E3 ubiquitin ligase facilitates cancer cell survival by promoting K63-linked polyubiquitination of caspase-8", CELL DEATH DIS, vol. 4, 2013, pages e935
LI, Y. ET AL.: "The HECTD3 E3 ubiquitin ligase suppresses cisplatin-induced apoptosis via stabilizing MALT1", NEOPLASIA, vol. 15, 2013, pages 39 - 48
HUANG, X. ET AL.: "Phosphorylation of Dishevelled by protein kinase RIPK4 regulates Wnt signaling", SCIENCE, vol. 339, 2013, pages 1441 - 5
EREZ, A. ET AL.: "Sil overexpression in lung cancer characterizes tumors with increased mitotic activity", ONCOGENE, vol. 23, 2004, pages 5371 - 7, XP002597454, DOI: doi:10.1038/SJ.ONC.1207685
EREZ, A. ET AL.: "The SIL gene is essential for mitotic entry and survival of cancer cells", CANCER RES, vol. 67, 2007, pages 4022 - 7
TANG, Y.; ORTH, J.D.; XIE, T.; MITCHISON, T.J.: "Rapid induction of apoptosis during Kinesin-5 inhibitor-induced mitotic arrest in HL60 cells", CANCER LETT, vol. 310, 2011, pages 15 - 24, XP028258225, DOI: doi:10.1016/j.canlet.2011.05.024
VENERE, M. ET AL.: "The mitotic kinesin KIF11 is a driver of invasion, proliferation, and self-renewal in glioblastoma", SCI TRANSL MED, vol. 7, 2015, pages 304ral43
LOGUE, J.S. ET AL.: "AKAP220 protein organizes signaling elements that impact cell migration", J BIOL CHEM, vol. 286, 2011, pages 39269 - 81
WHITING, J.L. ET AL.: "Protein Kinase A Opposes the Phosphorylation-dependent Recruitment of Glycogen Synthase Kinase 3beta to A-kinase Anchoring Protein 220", J BIOL CHEM, vol. 290, 2015, pages 19445 - 57
TANJI, C. ET AL.: "A-kinase anchoring protein AKAP220 binds to glycogen synthase kinase-3beta (GSK-3beta ) and mediates protein kinase A-dependent inhibition of GSK-3beta", J BIOL CHEM, vol. 277, 2002, pages 36955 - 61
TANAKA, M. ET AL.: "A novel RNA-binding protein, Ossa/C9orf10, regulates activity of Src kinases to protect cells from oxidative stress-induced apoptosis", MOL CELL BIOL, vol. 29, 2009, pages 402 - 13
BARTOLOME, R.A. ET AL.: "IL13 Receptor alpha2 Signaling Requires a Scaffold Protein, FAM120A, to Activate the FAK and PI3K Pathways in Colon Cancer Metastasis", CANCER RES, vol. 75, 2015, pages 2434 - 44
Attorney, Agent or Firm:
LEE, Cheo Young et al. (KR)
Download PDF: